Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AVIR Atea Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: AVIR
Price (delayed)
$2.74
Market cap
$234.49M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.65
Enterprise value
$116.54M
Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging its deep understanding
Highlights
The debt has declined by 35% year-on-year and by 12% since the previous quarter
Atea Pharmaceuticals's EPS has increased by 18% QoQ and by 16% YoY
Atea Pharmaceuticals's quick ratio has increased by 49% YoY but it has decreased by 20% QoQ
The company's equity fell by 18% YoY and by 6% QoQ
Key stats
What are the main financial stats of AVIR
Market
Valuations
Earnings
Shares outstanding
85.58M
Market cap
$234.49M
Enterprise value
$116.54M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.57
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$162.19M
Net income
-$139.49M
EBIT
-$138.59M
EBITDA
-$138.18M
Free cash flow
-$126.2M
Per share
Balance sheet
Liquidity
EPS
-$1.65
EPS diluted
-$1.65
Free cash flow per share
-$1.48
Book value per share
$4.81
Revenue per share
$0
TBVPS
$5.17
Total assets
$439.96M
Total liabilities
$28.88M
Debt
$1.45M
Equity
$411.08M
Working capital
$411.96M
Debt to equity
0
Current ratio
19.94
Quick ratio
19.56
Net debt/EBITDA
0.85
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-29.3%
Return on equity
-31.3%
Return on invested capital
-42.8%
Return on capital employed
-33.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AVIR stock price
How has the Atea Pharmaceuticals stock price performed over time
Intraday
5.79%
1 week
0.74%
1 month
-8.67%
1 year
-25.95%
YTD
-18.21%
QTD
-8.36%
Financial performance
How have Atea Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$162.19M
Net income
-$139.49M
Gross margin
N/A
Net margin
N/A
Atea Pharmaceuticals's net income has increased by 17% from the previous quarter and by 15% YoY
The operating income is up by 16% QoQ and by 16% YoY
Price vs fundamentals
How does AVIR's price correlate with its fundamentals
Growth
What is Atea Pharmaceuticals's growth rate over time
Valuation
What is Atea Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.57
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Atea Pharmaceuticals's EPS has increased by 18% QoQ and by 16% YoY
AVIR's P/B is 68% lower than its 5-year quarterly average of 1.8 and 5% lower than its last 4 quarters average of 0.6
The company's equity fell by 18% YoY and by 6% QoQ
Efficiency
How efficient is Atea Pharmaceuticals business performance
AVIR's return on invested capital is up by 14% since the previous quarter but it is down by 7% year-on-year
The company's return on equity rose by 13% QoQ but it fell by 7% YoY
The ROA has increased by 12% QoQ but it has decreased by 7% YoY
Dividends
What is AVIR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AVIR.
Financial health
How did Atea Pharmaceuticals financials performed over time
The current ratio has soared by 50% year-on-year but it has declined by 20% since the previous quarter
Atea Pharmaceuticals's quick ratio has increased by 49% YoY but it has decreased by 20% QoQ
The debt is 100% smaller than the equity
The debt has declined by 35% year-on-year and by 12% since the previous quarter
The company's equity fell by 18% YoY and by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.